Table 1 Associations of SLC6A1 protein expression with various clinicopathological characteristics of PCa patients
From: Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer
Clinicopathological Characteristics | IRS of SLC6A1 in our cohort (n, %) | SLC6A1 expression in TCGA dataset | |||||
|---|---|---|---|---|---|---|---|
Case | Low (n = 11) | High (n = 39) | P | Case | Mean ± S.D. | P | |
Age(years) | |||||||
< 66 | 20 | 7(35.0) | 13(65.0) | 0.070 | 355 | 15.05 ± 13.76 | 0.995 |
≥ 66 | 30 | 4(13.3) | 26(86.7) | 143 | 15.04 ± 10.67 | ||
Gleason score | |||||||
<8 | 31 | 6(19.4) | 25(80.6) | 0.564 | 292 | 12.47 ± 10.40 | < 0.001 |
≥ 8 | 19 | 5(26.3) | 14(73.7) | 206 | 18.69 ± 15.15 | ||
Clinical stage | |||||||
<T3A | 29 | 5(17.2) | 24(82.8) | 0.340 | 194 | 12.22 ± 10.25 | < 0.001 |
≥ T3A | 21 | 6(28.6) | 15(71.4) | 304 | 16.85 ± 14.12 | ||
Metastasis | |||||||
No | – | – | 416 | 14.45 ± 12.07 | 0.059 | ||
Yes | – | – | 82 | 18.09 ± 16.42 | |||
PSA failure | |||||||
No | – | – | 439 | 14.57 ± 12.69 | 0.042 | ||
Yes | – | – | 59 | 18.62 ± 14.31 | |||